Ascendis Pharma A/S’s (ASND) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report sent to investors on Monday,Benzinga reports. They currently have a $200.00 price target on the biotechnology company’s stock. Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group boosted their […]
Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report sent to investors on Monday,Benzinga reports. They currently have a $200.00 price target on the biotechnology company’s stock. Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group boosted their […]
